NTRC, Pelago Bioscience and Pangaea Oncology to collaborate in Eurostars project to develop a novel biomarker platform for immuno-oncology

June 11th 2020, Oss, Solna, Barcelona – NTRC, Pelago Bioscience and Pangaea Oncology today announced that they are developing a biomarker platform for new immuno-oncology drugs as part of a Eurostars collaboration. The biomarker platform will be based on the analysis of liquid biopsies from cancer patients. In this project, spanning over three years, having a budget of 2.5 million Euro, tumor and immune cells will be isolated from liquid biopsies at Pangaea; the tumor and immune cells will be used to develop co-culture assays at NTRC and target engagement binding assays at Pelago.

The platform fullfills the need to determine the functional activity of immuno-oncology drug candidates in patient-derived cellular models at an early stage, to prevent unnecessary clinical failure. The cell-based assay platform will be applicable for small molecules and biologics, such as therapeutic antibodies. In this Eurostars project, the companies will further develop their capabilities in the genetic and immunologic characterization of liquid biopsies and the performance of complex cell-based assays using primary materials. Finally, an integrated service for discovering novel biomarkers for cancer immunotherapy and determination of functional activity and target binding in cells will be developed. The integrated service will be made available to pharmaceutical companies, biotech, hospital and academic institutions worldwide.

Eurostars collaboration to develop a biomarker platform for Immuno-Oncology, consisting of markers for Target Engagement, Immune Markers, and Genomic Biomarkers. The Eurostars partners are NTRC (The Netherlands), Pelage Bioscience (Sweden), Pangaea Oncology (Spain).

NTRC provides cancer cell line profiling services (Oncolines™, SynergyFinder™) and profiling on primary patient materials. In addition, it performs in-depth mechanistic analyses in cells and by biophysical methods, such as Biacore and LC-MS/MS. The company is based in the Netherlands.

Pelago Bioscience in Sweden, has developed the patented CETSA® technology as a label free alternative to determine the binding of compounds to their targets in cells. Interactions are characterized and quantified by immunoblot analysis or proteomic profiling by mass spectrometry.

Pangea Oncology is a precision oncology service company with clinical healthcare activity through its subsidiary Dr. Rosell Oncology Institute. It supports personalized medicine based on genetic analysis. Its research activities focus on the development of novel diagnostic techniques, such as circulating tumor DNA (ctDNA).


test
  • Jun 15 2020   NTRC, Pelago Bioscience and Pangaea Oncology to collaborate in Eurostars project to develop a novel biomarker platform for immuno-oncology
  • May 18 2020   Novel screening assay for Arginase-1 inhibitors published in SLAS Discovery
  • Nov 29 2019   New structural insights into Arginase-1, a target for cancer immunotherapy
  • Nov 5 2019   Approach for Predictive Precision Medicine at ELRIG 2019 Drug Discovery Conference
  • Oct 21 2019   Predictive Precision Medicine Approaches at Molecular Targets and Cancer Therapeutics Conference
  • Mar 27 2019   NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer
  • Mar 20 2019   Effective discovery of synergistic combinations by in silico prioritization
  • Feb 12 2019   Tissue-type analysis included in Oncolines™ cancer cell line profiling
  • Nov 21 2018   NTRC expands ResidenceTimer™ kinase panel with CDKs, MERTK, TYRO3 and GSKβ
  • Nov 12 2018   NTRC launches the first High-throughput Screening Assay for Arginase-1 inhibitors at ENA2018
  • Nov 1 2018   New predictive drug response biomarkers for approved kinase inhibitors
  • Oct 28 2018   NTRC presents at Rare Diseases and Orphan Drugs conference
  • Sep 26 2018   Oncolines™ at Discovery on Target conference in Boston
  • Jun 29 2018   NTRC presents at European Association of Cancer Research conference in Amsterdam
  • Jun 10 2018   NTRC expands OncolinesProfiler™ reference compound database to 162 anti-cancer agents
  • Apr 11 2018   NTRC presents novel high-throughput screening assay for Arginase I inhibitors for cancer immunotherapy at AACR Annual Meeting in Chicago
  • Apr 5 2018   NTRC expands ResidenceTimer™ platform with BTK resistance mutants
  • Mar 25 2018   NTRC expands SynergyFinder™ platform with triple combination testing
  • Feb 22 2018   NTRC includes Growth Rate metric evaluation in Oncolines™ profiling
  • Nov 15 2017   NTRC at Pivot Oncology conference Breakthroughs in Precision Cancer Treatment
  • Nov 10 2017   Target residence time-guided lead optimization at the European Pharma Summit in Berlin
  • Oct 16 2017   Pharmacogenomic analysis at Molecular Targets and Cancer Therapeutics conference
  • Oct 11 2017   Novel synergistic combinations identified by unbiased high-throughput screening
  • Sep 25 2017   NTRC’s key TTK kinase inhibitor patent granted in US
  • Sep 19 2017   Meet NTRC at Discovery on Target conference in Boston 25 – 29 September, 2017
  • Jul 28 2017   NTRC publishes an association of CTNNB1 mutant status and increased cancer cell line sensitivity to TTK inhibitors
  • Jun 23 2017   NTRC expands Oncolines™ cell line panel to 102 cell lines
  • May 22 2017   NTRC publishes target residence time-guided optimization of TTK inhibitors
  • Mar 30 2017   NTRC launches GeneNominator™ tool for drug sensitivity and gene expression analysis
  • Mar 27 2017   Meet NTRC at booth #3050 AACR 2017 in Washington D.C.
  • Mar 16 2017   New study in Oncotarget shows that stable aneuploid cells are more sensitive to TTK inhibition than chromosomally unstable cell lines
  • Jan 2 2017   Kinetic parameters of 80 kinase inhibitors available online through the Journal of Molecular Biology
  • Dec 23 2016   Structural insight into the function of TDO in healthy aging
  • Dec 23 2016   New drug combinations addressing treatment resistance in childhood leukemia proposed based on SynergyFinder™
  • Dec 5 2016   NTRC’s Oncolines™ profiling is cover story in December issue of Molecular Cancer Therapeutics
  • Nov 10 2016   NTRC presents on ResidenceTimer™ and OncolinesProfiler™ at 28th EORTC-NCI-AACR symposium in Munich
  • Sep 18 2016   NTRC to join EU mission to Japan and to present at BIO Japan
  • Sep 2 2016   Comparative Oncolines™ profiling of 122 anti-cancer agents published in Molecular Cancer Therapeutics
  • Aug 25 2016   NTRC presents on ResidenceTimer™ at Discovery on Target conference in Boston
  • Jul 6 2016   NTRC presents OncolinesProfiler™ and TTK program at EACR in Manchester
  • Apr 28 2016   Novel synergistic drug combinations proposed for pediatric T-cell leukemia
  • Apr 8 2016   NTRC expands number of cancer genes analyzed in Oncolines™ cell line panel
  • Apr 8 2016   NTRC presents on TTK kinase program at AACR conference
  • Jan 15 2016   NTRC team of cyclists will conquer the Alpe d’Huez to raise funds for cancer research
  • Dec 9 2015   NTRC has identified IDO1 inhibitors with best-in-class properties by screening at the European Lead Factory
  • Dec 4 2015   NTRC and Vipergen receive Eurostars support for cancer immunotherapy research
  • Sep 14 2015   NTRC launches comparative cancer cell line profiling
  • Aug 31 2015   NTRC presents at Discovery on Target conference in Boston
  • Jul 10 2015   Novel therapeutic target proposed to increase the efficacy of taxane chemotherapy
  • Jul 8 2015   Whole genome doubling causes multidrug resistance
  • Jun 14 2015   NFK GreenScreen™ and TTK program presented at EACR-AACR conference in Florence
  • May 27 2015   Selective targeting of cancer driver genes by combinations of existing drugs published in PLOS ONE
  • Apr 28 2015   TTK drug discovery program presented at Protein Kinases conference in Berlin
  • Apr 7 2015   SynergyFinder™ presented at AACR 2015 in Philadelphia
  • Apr 7 2015   ResidenceTimer™ and TTK drug discovery program presented at Drug Discovery Chemistry meeting in San Diego
  • Apr 3 2015   NTRC receives Michael J. Fox Foundation support for TDO program for Parkinson’s disease
  • Feb 22 2015   TTK program and SynergyFinder™ presented at TAT 2015 conference in Paris
  • Feb 18 2015   NTRC receives qualified hit series for TDO from the European Lead Factory
  • Jan 15 2015   NTRC launches assay for mouse IDO1 and mouse TDO activity
  • Jan 7 2015   NTRC and Utrecht University start collaborative research project on Parkinson’s disease
  • Nov 12 2014   SynergyFinder™ and NFK GreenScreen™ presented at EORTC-NCI-AACR conference in Barcelona
  • Nov 12 2014   NFK GreenScreen™ presented at CHAINS conference in Veldhoven
  • Oct 1 2014   NTRC launches Oncolines™ 66 cell line panel
  • Sep 5 2014   ResidenceTimer™ will be presented at the EFMC-ISMC symposium 2014
  • Aug 25 2014   Reverse Phase Protein Array workshop in Paris sponsored by NTRC
  • Aug 25 2014   NTRC will present at 8th International Protein Kinase Inhibitors conference in Warsaw
  • Jun 27 2014   Oncolines™ and SynergyFinder™ presented at EACR 2014 in Munich
  • Jun 2 2014   NTRC publishes high-throughput screening assay for IDO1 and TDO in Journal of Biomolecular Screening
  • May 14 2014   NTRC will present at Discovery Partnerships Conference in Berlin
  • May 5 2014   NTRC will attend BIO 2014 in San Diego
  • May 5 2014   NTRC will present at Protein Kinases in Drug Discovery Conference in Berlin
  • Apr 13 2014   NTRC launches new service ResidenceTimer™ at Drug Discovery Chemistry conference in San Diego
  • Mar 27 2014   Oncolines™ and kinome profiling presented at AACR 2014 in San Diego
  • Mar 21 2014   NTRC publishes Oncolines™ profiles of all marketed small molecule kinase inhibitor drugs in PLOS ONE
  • Mar 7 2014   NTRC will present at Drug Discovery Innovations Conference 2014
  • Feb 15 2014   NTRC will present at Frontiers in Medicinal Chemistry 2014 in Tübingen.
  • Feb 6 2014   NTRC will present at BioEurope Spring 2014
  • Feb 6 2014   NTRC reaches new milestones in their drug discovery programs and expands business development activities
  • Dec 10 2013   NTRC extends the roll-out of its services Oncolines™ and SynergyFinder™ and the kinase profiling services of Carna Biosciences Inc.
  • Nov 12 2013   NTRC provides high-throughput screening services together with Pivot Park Screening Centre
  • Oct 14 2013   NTRC to partner with European centers of excellence in training network for next generation cancer researchers
  • Oct 13 2013   NTRC will present at BioEurope 2013
  • Sep 26 2013   Oncolines™ presented at the European Cancer Congress 2013
  • Nov 19 2012   NTRC and Carna join forces in the marketing of drug discovery services in Europe and Japan
  • Nov 13 2012   NTRC obtains exclusive license for Merck kinase candidate compounds
  • Jun 6 2012   NTRC starts at the Life Sciences Park Oss